Literature DB >> 3486075

Reduced in vivo leucocyte migration and elastase and lysozyme concentrations in skin chamber experiments with piroxicam in healthy volunteers.

A Scheja, A Forsgren, K Ohlsson, F A Wollheim.   

Abstract

Leucocyte migration in vivo, studied with a skin chamber technique was inhibited in eight healthy volunteers after six days' medication with piroxicam, 20 mg a day, but not after only one day's medication. The inhibition was not correlated to the serum content of the drug. The median trough values of piroxicam in serum were 2.5 mg/l and in blister fluid 1.2 mg/l after six days' medication. Leucocyte migration in vitro under agarose was not inhibited after six days' medication with piroxicam. When normal polymorphonuclear leucocytes were incubated with piroxicam in vitro migration under agarose was inhibited but only at piroxicam concentrations higher than those attainable in clinical therapy. The concentrations of elastase and lysozyme in the skin chamber decreased after six days' medication with piroxicam.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486075

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Serum cytidine deaminase levels after withdrawal of non-steroidal anti-inflammatory treatment in rheumatoid arthritis.

Authors:  P W Thompson; J R Kirwan; D D Jones; H L Currey
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

2.  Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients.

Authors:  C Montecucco; A Mazzone; D Pasotti; R Caporali; M Longhi; D Casilli; G Ricevuti; P Fratino; M P Ruffilli
Journal:  Inflammation       Date:  1989-04       Impact factor: 4.092

3.  Interference Assessment of Various Endogenous and Exogenous Substances on the Performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System.

Authors:  Carrie Lorenz; Wendolyn Sandoval; Mark Mortellaro
Journal:  Diabetes Technol Ther       Date:  2018-03-30       Impact factor: 6.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.